<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03488719</url>
  </required_header>
  <id_info>
    <org_study_id>TM004</org_study_id>
    <nct_id>NCT03488719</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate</brief_title>
  <official_title>A Phase 1 Study to Examine Pharmacodynamic Interaction Between Tesofensine and Metoprolol on 24-hours Mean Heart Rate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saniona</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saniona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 Study to Examine Pharmacodynamic Interaction Between Tesofensine and Metoprolol on
      24-hours Mean Heart Rate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the dose-response relationship between tesofensine and metoprolol will be
      examined and thus the optimal dose of metoprolol to mitigate the effects of tesofensine on HR
      will be determined. HR is the primary endpoint because in the previous studies it has been
      shown to be the most affected safety endpoint by the effects of tesofensine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each subject will participate in a Screening Period (Day 28 to Day 3), a Baseline Period (Day -2 to Day -1) and a Treatment Period (Day 1 to Day 24) and will have two Follow-up phone calls (Day 30 and Day 50).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Tesofensine dosing will be performed open-label. Metoprolol dosing will be performed &quot;single-blind&quot;.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-response relationship</measure>
    <time_frame>Day 1 to Day 24</time_frame>
    <description>The dose of metoprolol which will bring about no change in M24HR for each respective dose of tesofensine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitigation effect</measure>
    <time_frame>Day 1 to Day 24</time_frame>
    <description>The dose of metoprolol which will mitigate the HR increasing effects of tesofensine</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Phase 1</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesofensine 0.25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesofensine 0.50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tesofensine 0.75mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol Succinate 25 MG</intervention_name>
    <description>Metoprolol 25mg</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Metoprolol 25mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol Succinate 50 MG</intervention_name>
    <description>Metoprolol 50mg</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol Succinate 100 MG</intervention_name>
    <description>Metoprolol 100mg</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject voluntarily agrees to participate in this study and signs an Independent
             Ethics Committee (IEC)-approved informed consent prior to performing any of the
             Screening procedures.

          2. Male and female subjects between 18 to 60 years of age, inclusive, at Screening.

          3. Non-smokers (or other nicotine use) as determined by history (no nicotine use over the
             past 6 months) and by urine cotinine concentration (&lt; 500 ng/mL) at Screening and
             admissions.

          4. Body mass index (BMI) between â‰¥ 27 and &lt; 40 kg/m2 at Screening.

        Exclusion Criteria:

          1. Subject has history or evidence of any clinically significant cardiovascular,
             gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic (e.g.,
             diabetes), urologic, pulmonary (e.g., asthma or chronic obstructive pulmonary
             disease), neurologic, dermatologic, psychiatric, renal, and/or other major disease or
             malignancy as judged by the Investigator.

          2. Subject has any disorder that would interfere with the absorption, distribution,
             metabolism or excretion of drugs.

          3. Subject has a clinically significant abnormality following the Investigator's review
             of the physical examination, ECG and clinical study protocol-defined clinical
             laboratory tests at Screening or admission to the clinical unit or has any concurrent
             disease or condition that, in the opinion of the Investigator, would make the subject
             unsuitable for participation in the clinical study. One re-test is allowed, if (a)
             test result(s) is outside the limits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Dvorak, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Saniona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorgen Drejer, PhD</last_name>
    <phone>70 705 225</phone>
    <phone_ext>+45</phone_ext>
    <email>jd@saniona.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roman Dvorak, MD, PhD</last_name>
    <phone>70 705 225</phone>
    <phone_ext>+45</phone_ext>
    <email>rdv@saniona.com</email>
  </overall_contact_backup>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

